EMERGENT

📅 Upcoming

🕒 Recent(90d)

News

• Early Alert: Intraosseous Needle Set Issue from Becton Dickinson
  BD is recalling certain BD Intraosseous Vascular Access System Needle Sets due to difficulty removing the obturator (stylet) following placement.
  fda_medwatch · 1d ago
• MapLight CEO on what investors missed in the biotech’s schizophrenia data
  Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."
  biopharma_dive · 6d ago
• MapLight dives despite positive data for schizophrenia drug
  Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
  biopharma_dive · 8d ago
• MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
  While MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb's Cobenfy is likely to hold its market share.
  biospace · 8d ago
• Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
  To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
  biopharma_dive · 13d ago
• Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
  Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
  biopharma_dive · 1mo ago
• FDA Approves First Single-Dose Generic Treatment for Influenza
  The U.S. Food and Drug Administration today approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment for acute uncomplicated influenza and prophylaxis in…
  fda_press · 1mo ago
• Study data convince Lundbeck to push new migraine drug forward
  A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.
  biopharma_dive · 2mo ago
• Opinion: How living and practicing medicine abroad complicated my beliefs about universal health care systems
  “I believe deeply in universal health care. But universal care must also mean universal safety and accountability, not merely universal access.”
  stat · 2mo ago
• Opinion: What should hospitals do when patients demand unvaccinated donor blood?
  “You have to understand a person's belief if you want to address it,” Deva Sharma says on the “First Opinion Podcast” about requests for unvaccinated donor blood.
  stat · 2mo ago